PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial
Norgren L, Weiss N, Nikol S, Lantis JC, Patel MR, Hinchliffe RJ et al.
Br J Surg 2024; 111: znad437.
This study included 143 patients with limb-threatening ischaemia, unsuitable for standard treatment. Intramuscular injections of placental-derived mesenchymal cells, 60 days apart did not affect amputation-free survival: 28.6 per cent, versus 33 per cent with placebo. The effect was more positive in non-diabetics.
Comment: Interesting subgroup analysis that may be the basis for further study.
12 March 2024
Read paperAcademy
Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
